Bocom International Reiterates 'Buy' on GENFLEET-B with HK$58 Target Price

Stock News11:42

Bocom International has issued a research report maintaining its investment rating and price target for GENFLEET-B (ASX: 02595) at 'Buy' and HK$51, respectively.

The bank noted that the overseas clinical development and partnership progress for the KRAS G12D inhibitor are progressing favorably.

Bocom International believes that the strong preliminary overseas data provides further evidence supporting the best-in-class potential of VS7375.

In the second half of 2026, Verastem is expected to disclose additional efficacy data from the TARGET-D 101 study, which warrants close attention.

Other key overseas catalysts include: 1) completing patient enrolment for the TARGET-D 101 pancreatic cancer and NSCLC monotherapy cohorts and the CRC combination cohort by the end of June; 2) discussing the design of a first-line Phase III study with the FDA by the end of 2026 and initiating patient enrolment in the first half of 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101313110?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 11:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101313110","market":"nz","top_or_hot":-1,"title":"Bocom International Reiterates 'Buy' on GENFLEET-B with HK$58 Target Price","media":"Stock News","content":"<p>Bocom International has issued a research report maintaining its investment rating and price target for <b>GENFLEET-B</b> (<b>ASX: 02595</b>) at 'Buy' and HK$51, respectively.<br><br>The bank noted that the overseas clinical development and partnership progress for the KRAS G12D inhibitor are progressing favorably.<br><br>Bocom International believes that the strong preliminary overseas data provides further evidence supporting the best-in-class potential of VS7375.<br><br>In the second half of 2026, Verastem is expected to disclose additional efficacy data from the TARGET-D 101 study, which warrants close attention.<br><br>Other key overseas catalysts include: 1) completing patient enrolment for the TARGET-D 101 pancreatic cancer and NSCLC monotherapy cohorts and the CRC combination cohort by the end of June; 2) discussing the design of a first-line Phase III study with the FDA by the end of 2026 and initiating patient enrolment in the first half of 2027.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bocom International Reiterates 'Buy' on GENFLEET-B with HK$58 Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBocom International Reiterates 'Buy' on GENFLEET-B with HK$58 Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-25 11:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bocom International has issued a research report maintaining its investment rating and price target for <b>GENFLEET-B</b> (<b>ASX: 02595</b>) at 'Buy' and HK$51, respectively.<br><br>The bank noted that the overseas clinical development and partnership progress for the KRAS G12D inhibitor are progressing favorably.<br><br>Bocom International believes that the strong preliminary overseas data provides further evidence supporting the best-in-class potential of VS7375.<br><br>In the second half of 2026, Verastem is expected to disclose additional efficacy data from the TARGET-D 101 study, which warrants close attention.<br><br>Other key overseas catalysts include: 1) completing patient enrolment for the TARGET-D 101 pancreatic cancer and NSCLC monotherapy cohorts and the CRC combination cohort by the end of June; 2) discussing the design of a first-line Phase III study with the FDA by the end of 2026 and initiating patient enrolment in the first half of 2027.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1101313110","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101313110","pubTimestamp":1782358943,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Bocom International has issued a research report maintaining its investment rating and price target for GENFLEET-B (ASX: 02595) at 'Buy' and HK$51, respectively.The bank noted that the overseas...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1574":"生物医药B类股","EWH":"香港ETF-iShares MSCI","09939":"开拓药业-B","02595":"劲方医药-B","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"交银国际重申GENFLEET-B“买入”目标价58港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"EWH":1,"02595":1,"09939":1},"content_text":"Bocom International has issued a research report maintaining its investment rating and price target for GENFLEET-B (ASX: 02595) at 'Buy' and HK$51, respectively.The bank noted that the overseas clinical development and partnership progress for the KRAS G12D inhibitor are progressing favorably.Bocom International believes that the strong preliminary overseas data provides further evidence supporting the best-in-class potential of VS7375.In the second half of 2026, Verastem is expected to disclose additional efficacy data from the TARGET-D 101 study, which warrants close attention.Other key overseas catalysts include: 1) completing patient enrolment for the TARGET-D 101 pancreatic cancer and NSCLC monotherapy cohorts and the CRC combination cohort by the end of June; 2) discussing the design of a first-line Phase III study with the FDA by the end of 2026 and initiating patient enrolment in the first half of 2027.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101313110","isCrawlerRequest":true}